Longeveron LLC earnings missed by $0.28, revenue fell short of estimates

Longeveron reported Q3 2026 revenue of $115,000 and a net loss of $6.1 million, with cash expected to last until Q1 2027. Its Phase 2b ELPIS II trial did not meet the primary endpoint, but showed fewer major adverse cardiac events in the treatment group. The company is exploring strategic and financing options.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update ● Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps

Longeveron Inc. (LGVN) reported that its Phase 2b trial of laromestrocel for hypoplastic left heart syndrome met a secondary endpoint, showing fewer major adverse cardiac events compared to standard care, despite missing the primary endpoint. The trial involved 40 infants and followed them for 12 months. LGVN plans to discuss the results with the FDA and will present findings at the American Heart Association's Scientific Sessions. LGVN shares are up 5.66% at $1.69.

Longeveron reported that its drug laromestrocel showed fewer major adverse cardiac events than standard care in the ELPIS II trial, though it missed the primary endpoint. The secondary endpoint results were statistically significant, with 8 events in the standard care group versus 1 in the treatment group. The company plans to meet with the FDA to discuss next steps. Data will be presented at the AHA 2026 Scientific Sessions.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) Important Secondary Clinical Outcome Endpoint MACE Achieved Statistical Significance ELPIS II 2 Dat

Longeveron Inc. reported that its ELPIS II trial for HLHS failed the primary endpoint but showed improvement in the MACE secondary endpoint. The company plans to seek an FDA meeting. Safety data was acceptable.